Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Pascal M BurgerJannick A N DorresteijnAernoud T L FioletStefan KoudstaalJohn William EikelboomStefan Mark NidorfPeter L ThompsonJan-Hein CornelCharley A BudgeonIris C D WestendorpDriek P W BeelenFabrice M A C MartensP Gabriel StegFolkert W. AsselbergsMaarten J CramerMartin TeraaDeepak L BhattFrank L J VisserenArend Mosterdnull nullnull nullnull nullPublished in: European journal of preventive cardiology (2023)
The absolute benefits of low-dose colchicine vary between individual patients with chronic CAD. They may be expected to be of at least similar magnitude to those of intensified LDL-c and SBP reduction in a majority of patients already on conventional lipid-lowering and blood pressure-lowering therapy.
Keyphrases
- low dose
- coronary artery disease
- blood pressure
- end stage renal disease
- high dose
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- percutaneous coronary intervention
- peritoneal dialysis
- stem cells
- heart rate
- coronary artery bypass grafting
- cardiovascular disease
- aortic stenosis
- glycemic control